These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group. J Clin Oncol; 2005 Oct 20; 23(30):7483-90. PubMed ID: 16234514 [Abstract] [Full Text] [Related]
4. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C. Hum Pathol; 2012 Sep 20; 43(9):1363-75. PubMed ID: 22204715 [Abstract] [Full Text] [Related]
5. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. Figl A, Scherer D, Nagore E, Bermejo JL, Dickes E, Thirumaran RK, Gast A, Hemminki K, Kumar R, Schadendorf D. Mutat Res; 2009 Feb 10; 661(1-2):78-84. PubMed ID: 19073198 [Abstract] [Full Text] [Related]
6. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, Mouridsen HT. Acta Oncol; 2008 Feb 10; 47(4):725-34. PubMed ID: 18465341 [Abstract] [Full Text] [Related]
8. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Paré L, Altés A, Ramón y Cajal T, Del Rio E, Alonso C, Sedano L, Barnadas A, Baiget M. Anticancer Drugs; 2007 Aug 10; 18(7):821-5. PubMed ID: 17581305 [Abstract] [Full Text] [Related]
14. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells. Kopjar N, Milas I, Garaj-Vrhovac V, Gamulin M. Clin Exp Med; 2006 Dec 10; 6(4):177-90. PubMed ID: 17191110 [Abstract] [Full Text] [Related]
15. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer. Przybylowska-Sygut K, Stanczyk M, Kusinska R, Kordek R, Majsterek I. Clin Breast Cancer; 2013 Feb 10; 13(1):61-8. PubMed ID: 23103366 [Abstract] [Full Text] [Related]
16. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. Yonemori K, Katsumata N, Kaneko M, Uno H, Matsumoto K, Kouno T, Shimizu C, Ando M, Takeuchi M, Fujiwara Y. Breast Cancer Res Treat; 2007 Jul 10; 103(3):313-8. PubMed ID: 17063267 [Abstract] [Full Text] [Related]
18. Polymorphisms in three base excision repair genes and breast cancer risk in Thai women. Sangrajrang S, Schmezer P, Burkholder I, Waas P, Boffetta P, Brennan P, Bartsch H, Wiangnon S, Popanda O. Breast Cancer Res Treat; 2008 Sep 10; 111(2):279-88. PubMed ID: 17922186 [Abstract] [Full Text] [Related]
20. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. J Natl Cancer Inst; 2008 Jan 02; 100(1):14-20. PubMed ID: 18159072 [Abstract] [Full Text] [Related] Page: [Next] [New Search]